Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters

Country/Region as subject
Language
Publication year range
1.
N Engl J Med ; 379(18): 1745-1753, 2018 11 01.
Article in English | MEDLINE | ID: mdl-30332564

ABSTRACT

During 2018, an unusual increase in Lassa fever cases occurred in Nigeria, raising concern among national and international public health agencies. We analyzed 220 Lassa virus genomes from infected patients, including 129 from the 2017-2018 transmission season, to understand the viral populations underpinning the increase. A total of 14 initial genomes from 2018 samples were generated at Redeemer's University in Nigeria, and the findings were shared with the Nigerian Center for Disease Control in real time. We found that the increase in cases was not attributable to a particular Lassa virus strain or sustained by human-to-human transmission. Instead, the data were consistent with ongoing cross-species transmission from local rodent populations. Phylogenetic analysis also revealed extensive viral diversity that was structured according to geography, with major rivers appearing to act as barriers to migration of the rodent reservoir.


Subject(s)
Genome, Viral , Lassa Fever/virology , Lassa virus/genetics , RNA, Viral/analysis , Adolescent , Adult , Animals , Bayes Theorem , Disease Reservoirs , Female , Genetic Variation , Humans , Lassa Fever/epidemiology , Lassa Fever/transmission , Male , Markov Chains , Middle Aged , Nigeria/epidemiology , Phylogeny , Phylogeography , Rodentia , Sequence Analysis, RNA , Zoonoses/transmission
2.
J Virol ; 93(21)2019 11 01.
Article in English | MEDLINE | ID: mdl-31413134

ABSTRACT

Lassa virus is genetically diverse with several lineages circulating in West Africa. This study aimed at describing the sequence variability of Lassa virus across Nigeria and inferring its spatiotemporal evolution. We sequenced and isolated 77 Lassa virus strains from 16 Nigerian states. The final data set, including previous works, comprised metadata and sequences of 219 unique strains sampled between 1969 and 2018 in 22 states. Most of this data originated from Lassa fever patients diagnosed at Irrua Specialist Teaching Hospital, Edo State, Nigeria. The majority of sequences clustered with the main Nigerian lineages II and III, while a few sequences formed a new cluster related to Lassa virus strains from Hylomyscus pamfi Within lineages II and III, seven and five sublineages, respectively, were distinguishable. Phylogeographic analysis suggests an origin of lineage II in the southeastern part of the country around Ebonyi State and a main vector of dispersal toward the west across the Niger River, through Anambra, Kogi, Delta, and Edo into Ondo State. The frontline of virus dispersal appears to be in Ondo. Minor vectors are directed northeast toward Taraba and Adamawa and south toward Imo and Rivers. Lineage III might have spread from northern Plateau State into Kaduna, Nasarawa, Federal Capital Territory, and Bauchi. One sublineage moved south and crossed the Benue River into Benue State. This study provides a geographic mapping of lineages and phylogenetic clusters in Nigeria at a higher resolution. In addition, we estimated the direction and time frame of virus dispersal in the country.IMPORTANCE Lassa virus is the causative agent of Lassa fever, a viral hemorrhagic fever with a case fatality rate of approximately 30% in Africa. Previous studies disclosed a geographical pattern in the distribution of Lassa virus strains and a westward movement of the virus across West Africa during evolution. Our study provides a deeper understanding of the geography of genetic lineages and sublineages of the virus in Nigeria. In addition, we modeled how the virus spread in the country. This knowledge allows us to predict into which geographical areas the virus might spread in the future and prioritize areas for Lassa fever surveillance. Our study not only aimed to generate Lassa virus sequences from across Nigeria but also to isolate and conserve the respective viruses for future research. Both isolates and sequences are important for the development and evaluation of medical countermeasures to treat and prevent Lassa fever, such as diagnostics, therapeutics, and vaccines.


Subject(s)
Lassa Fever/virology , Lassa virus/classification , Animals , Evolution, Molecular , Genetic Variation , Humans , Lassa Fever/epidemiology , Lassa Fever/transmission , Lassa virus/genetics , Murinae/virology , Nigeria/epidemiology , Phylogeny , Phylogeography
3.
Sci Rep ; 10(1): 16030, 2020 09 29.
Article in English | MEDLINE | ID: mdl-32994446

ABSTRACT

Lassa virus (LASV) is the causative agent of Lassa fever, an often-fatal hemorrhagic disease that is endemic in West Africa. Seven genetically distinct LASV lineages have been identified. As part of CEPI's (Coalition for Epidemic Preparedness Innovations) Lassa vaccine development program, we assessed the potential of the human immune system to mount cross-reactive and cross-protective humoral immune responses to antigens from the most prevalent LASV lineages, which are lineages II and III in Nigeria and lineage IV in Sierra Leone. IgG and IgM present in the blood of Lassa fever survivors from Nigeria or Sierra Leone exhibited substantial cross-reactivity for binding to LASV nucleoprotein and two engineered (linked and prefusion) versions of the glycoproteins (GP) of lineages II-IV. There was less cross-reactivity for the Zinc protein. Serum or plasma from Nigerian Lassa fever survivors neutralized LASV pseudoviruses expressing lineage II GP better than they neutralized lineage III or IV GP expressing pseudoviruses. Sierra Leonean survivors did not exhibit a lineage bias. Neutralization titres determined using LASV pseudovirus assays showed significant correlation with titres determined by plaque reduction with infectious LASV. These studies provide guidance for comparison of humoral immunity to LASV of distinct lineages following natural infection or immunization.


Subject(s)
Cross Reactions/immunology , Lassa Fever/immunology , Lassa virus/immunology , Antibodies/immunology , Antibodies, Viral/immunology , Antigens, Viral/immunology , Genetic Variation , Humans , Immunity, Humoral , Immunization , Lassa virus/pathogenicity , Nigeria/epidemiology , Nucleoproteins , Recombinant Proteins , Sierra Leone/epidemiology , Survivors
4.
Idowu Bolade Olawoye; Paul Eniola Oluniyi; Edyth Parker; Judith Uche Oguzie; Jessica Nnenna Uwanibe; Tolulope Adeyemi Kayode; Fehintola Victoria Ajogbasile; Testimony Jesupamilerin Olumade; Philomena Eromon; Priscilla Abechi; Tope Sobajo; Chinedu Ugwu; George Uwem; Femi Ayoade; Kazeem Akano; Oluwasemilogo Oluwasekunolami Akinlo; Julie Oreoluwa Akin-John; Nicholas Oyejide; Olubukola Ayo-Ale; Benjamin Adegboyega; Grace Chizaramu Chukwu; Ayomide Adeleke; Grace Opemipo Ezekiel; Farida Brimmo; Olanrewaju Odunyemi Fayemi; Iyanuoluwa Fred-Akintunwa; Ibrahim F. Yusuf; Testimony Oluwatise Ipaye; Oluwagboadurami John; Ahmed Iluoreh Muhammad; Deborah Chisom Nwodo; Olusola Akinola Ogunsanya; Johnson Okolie; Abolade Esther Omoniyi; Iyobosa Beatrice Omwanghe; Oludayo Oluwaseyi Ope-ewe; Shobi Otitoola; Kemi Adedotun-Suleiman; Courage Philip; Mudasiru Femi Saibu; Ayotunde Elijah Sijuwola; Christabel Anamuma Terkuma; Augustine Abu; Johnson Adekunle Adeniji; Moses Olubusuyi Adewunmi; Olufemi Oluwapelumi Adeyemi; Rahaman Ahmed; Anthony Ahumibe; Anthony Nnennaya Ajayi; Olusola Akanbi; Olatunji Akande; Monilade Akinola; Afolabi Akinpelu; George Akpede; Ekanem Anieno; Antjony E. Atage; Oyeronke Ayansola; Marycelin Baba; Olajumoke Babatunde; Bamidele Soji Oderinde; Ebo Benevolence; Osiemi Blessing; Mienye Bob-Manuel; Andrew Bock-Oruma; Aire Chris; Chimaobi Chukwu; Funmi Daramola; Adomeh Donatus; Rosemay Duruihuoma; Yerumoh Edna; Matthew Ekeh; Erim Ndoma; Richard Ewah; Akinwumi Fajola; Enoch Olowatosin Fakayode; Adeola Fowotade; Galadima Gadzama; Daniel Igwe; Odia Ikponmwosa; Rafiu Olasunkanmi Isamotu; Agbukor Jacqueline; Aiyepada John; Julie Johnson Ekpo; Ibrahim Kida; Nwando Mba; Airende Micheal; Mirabeau Youtchou Tatfeng; Worbianueri Beatrice Moore-Igwe; Anietie Moses; Okonofua Naregose; Nsikak-Abasi Ntia; Ifeanyi Nwafor; Elizabeth Odeh; Ephraim Ogbaini; Kingsley Chiedozie Ojide; Sylvanus Okogbenin; Peter Okokhere; Sylvanus Okoro; Azuka Okwuraiwe; Olisa Olasunkanmi; Oluseyi Olayinka; Adesuyi Omoare; Ewean Chukwuma Omoruyi; Hannah E. Omunakwe; Emeka Onwe Ogah; Chika Onwuamah; Venatious Onyia; Akhilomen Patience; Ebhodaghe Paulson; Omiunu Racheal; Esumeh Rita; Giwa Rosemary; Joseph Shaibu; Joseph Shaibu; Ehikhametalor Solomon; Ngozi Ugwu; Collins Nwachi Ugwu; Kingsley Ukwuaja; Zara Wudiri; Nnaemeka Ndodo; Brittany Petros; Bronwyn Mcannis; Cyril Oshomah; Femi Oladiji; Katherine J. Siddle; Rosemary Audu; Babatunde Lawal Salako; Stephen Schaffner; Danny Park; Ifedayo Adetifa; Chikwe Ihekweazu; Oyewale Tomori; Anise Nkenjop Happi; Onikepe Folarin; Kristian G. Andersen; Pardis C. Sabeti; Christian Tientcha Happi.
Preprint in English | PREPRINT-MEDRXIV | ID: ppmedrxiv-22280269

ABSTRACT

Identifying the dissemination patterns and impacts of a virus of economic or health importance during a pandemic is crucial, as it informs the public on policies for containment in order to reduce the spread of the virus. In this study, we integrated genomic and travel data to investigate the emergence and spread of the B.1.1.318 and B.1.525 variants of interest in Nigeria and the wider Africa region. By integrating travel data and phylogeographic reconstructions, we find that these two variants that arose during the second wave emerged from within Africa, with the B.1.525 from Nigeria, and then spread to other parts of the world. Our results show how regional connectivity in downsampled regions like Africa can often influence virus transmissions between neighbouring countries. Our findings demonstrate the power of genomic analysis when combined with mobility and epidemiological data to identify the drivers of transmission in the region, generating actionable information for public health decision makers in the region.

SELECTION OF CITATIONS
SEARCH DETAIL